NEW YORK (GenomeWeb News) — Shares in Affymetrix were up 17.74 percent, or $4.09, at $26.72 this afternoon after the company yesterday released its third-quarter earnings.
 
Today, investment bank UBS upgraded its rating of Affy shares to ‘Neutral’ from ‘Reduce.’
 
As GenomeWeb News reported yesterday, Affy said that third-quarter revenue increased around 1 percent as last year's profit swung to a loss.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.